All filters
Slidesets
Longer duration of virological suppression and a fully active companion drug ensure a high rate of virological control in HIV-1 infected patients switching to a dual therapy containing integrase inhibitors- Daniele Armenia
Presented at:
European HIV Clinical Forum 2018
Slidesets
Integrase inhibitors in specific populations- Women and those aging with HIV- Sharon Walmsley, FRCPC, MD, MSC
Presented at:
European HIV Clinical Forum 2018
Slidesets
Long-acting ARV for treatment & prevention: clinical considerations- Laura Waters, MD, FRCP
Presented at:
European HIV Clinical Forum 2018
Slidesets
Pharmacologic characteristics and delivery options for integrase inhibitors- Courtney Fletcher, PharmD
Presented at:
European HIV Clinical Forum 2018
Slidesets
Intergrase inhibitors- What's new?-Margaret Johnson, MD
Presented at:
European HIV Clinical Forum 2018
Slidesets
Resistance to integrase inhibitors- What clinicians need to know- Roger Paredes, MD, PhD
Presented at:
European HIV Clinical Forum 2018
Slidesets
Reduced drug regimens- What are the data?- Jose Arribas, MD
Presented at:
European HIV Clinical Forum 2018
Slidesets
Switching antiretroviral therapy to safer strategies based on intergrase inhibitors- Pedro Cahn, MD, PhD
Presented at:
European HIV Clinical Forum 2018